More Than 1 Million Americans Are Taking Ozempic and Other GLP-1s Without an Approved Reason. Is That Actually a Problem?

Ed Cara· Sep 24, 2026 · 4:50 PM UTC ·4 min read · 0 reactions · 0 comments · 5 views

More from Gizmodo tech Compare coverage Trending Talk Blindspots Daily Sources Live wire

#more #than #million #americans #taking

TL;DR · WeSearch summary

Key facts

▪GLP-1 medications like semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) have fast become some of the most recognizable and popular drugs in the world.
▪Recent research now shows that a sizable number of Americans have been taking GLP-1s off-label.
▪Scientists at New York University and others examined the medical records of Americans across the country.

About this source

Gizmodo files mainly under tech. We currently carry 1,311 of its stories.

All Gizmodo coverage →

Original article

Gizmodo · Ed Cara

Read full at Gizmodo →

Story provenance

Source · retrieval · rights · ranking — open for full record

inspect →

Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.

Record

Original publisher	Gizmodo
Canonical URL	https://gizmodo.com/more-than-1-million-americans-are-taking-ozempic-and-other-glp-1s-without-an-approved-reason-is-that-actually-a-problem-2000816772
Publication time	Thu, 24 Sep 2026 16:50:11 +0000
Retrieval time	2026-09-24T16:55:26.261Z
Last seen	2026-09-24T16:55:26.261Z
Headline source	Publisher (no WeSearch rewrite)
Excerpt source	publisher body
Excerpt method	First ~120 words (~800 chars) of extracted publisher body, fair-use limited.
Summary	WeSearch · cerebras-chat (WeSearch summarizer)
Summary source text	contentText
Citation coverage	Summary is a WeSearch-generated derivative; primary citation is the original publisher URL.
Cluster	gVIZdGJZ5OV_ · 1 stories
Cluster logic	Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison.
Ranking reason	Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking.
Publisher visit	Yes — open original
Substitutes article?	No — link-out required for full text

Rights status (four layers)

Publisher-declared

No publisher-confirmed rights record for this source yet.

Machine-readable

No source-specific machine-readable restriction detected beyond the public feed.

WeSearch interpretation

WeSearch declared handling (basis: Derived from the published RSS/Atom feed). This is WeSearch policy, not a legal grant on the publisher's behalf.

Unknown

Retrieval and training permissions are not asserted unless the publisher confirms them.

WeSearch handling by dimension

Indexing	May the item be indexed (stored, ranked, made findable)?	Allowed
Snippet	May a short excerpt of the publisher's text be shown?	Allowed
AI summary	May WeSearch generate its own short summary of the article?	Limited
Retrieval / RAG	May the content be exposed for third-party retrieval-augmented generation?	Not asserted
Model training	May the content be used to train AI models?	Not asserted
Commercial reuse	May the content be reused commercially?	Not permitted

Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.

Open original publisher → Source rights JSON → Machine-readable provenance → Rights framework → WESEARCH-STORY-PROVENANCE-V1

Opening excerpt (first ~120 words) tap to expand

GLP-1 medications like semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) have fast become some of the most recognizable and popular drugs in the world. Recent research now shows that a sizable number of Americans have been taking GLP-1s off-label. Scientists at New York University and others examined the medical records of Americans across the country. Since 2021, they found that at least 1.1 million Americans were prescribed a GLP-1 without having an FDA-approved indication for its use, such as obesity or type 2 diabetes. Though some people may be taking these drugs off-label for valid reasons, we’re largely in the dark about the overall harms of doing so, the researchers say.

…

Excerpt limited to ~120 words for fair-use compliance. The full article is at Gizmodo.

Anonymous · no account needed

Discussion

0 comments